EMBC Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -0.15%, SMA50 -7.86%, SMA200 -14.05%). The stock’s 14-day RSI is 44.62 (neutral), while the ATR of 0.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.6% below its high and over 13.91% above its low. Average 10-day trading volume of 3.38 million shares is significantly above the 3-month average of 1.14 million, indicating heightened recent market interest.

Wall Street analysts project EPS growth of 0.34% annually over the next five years. The latest quarter delivered EPS of $0.71. The next quarter is forecast at $0.42. Next year's EPS is expected at $10.99. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $12.00. The high target offers 541.03% upside. The low target suggests 207.69% downside. The mean target is $17.40. This offers 346.15% upside. Embecta Corp. earnings surprise history is a mixed track record. The quarter that ended February 05, 2026, missed forecasts by 5.97%.

Embecta Corp. has 58.49 million shares outstanding. The public float is 57.24 million shares, elevated short interest at 7.46% of float. This equals 3.11 million shares. The short ratio is 5.37 days. Institutional investors hold 102.03% of the float. Insiders own 0.47%. Kurdikar Devdatt holds 244.79 thousand shares, Melcher David F has 86.68 thousand shares and Elguicze Jacob has 66.03 thousand shares.

Embecta Corp. last paid a dividend of 0.6 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $24.60. This means the shares are trading below this model’s fair value.

Embecta Corp. (NASDAQ:EMBC) closed at $3.90 USD, losing -$5.35 (-57.84%) from the previous close of $9.25. The stock is currently trading near its 52-week low $3.90 and $15.55. With a market capitalization of about $230.96 million, Embecta Corp. is classified as a micro-cap and shows market-like volatility (beta ~1.05). Key stats such as the average daily volume over the past year has been around 859.17 thousand shares, trading with heavier-than-usual volume. Headquartered in Parsippany, NJ, Embecta Corp. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Devdatt Kurdikar, the company employs approximately 2,000 people and listed since March 22, 2022. Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes.

Embecta Corp. trades at a P/E ratio of 2.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.23 and a price-to-book ratio of -0.38 indicating negative book value, which may reflect financial stress. The P/FCF stands at 1.18, also above market averages.

Embecta Corp. (NASDAQ:EMBC) shares are flat 3.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Embecta Corp. trading at a premium to the broader market with a P/E of 2.13. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $21.22, suggesting 444.1% upside. Our AI forecast model points to short-term strength (62.05% over two weeks), a medium-term rise (58.46% over three months), and a longer-term gain (63.33% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Embecta Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 62.05%, with price expected at $6.32 by May 19, 2026, within a range of $5.48 to $7.09 3-Month Outlook: Projected rise of 58.46%, reaching $6.18 by August 03, 2026, with a range of $5.79 to $6.56. 1-Year Outlook: Projected gain of 63.33%, with price at $6.37 by May 05, 2027, within a range of $0.00 to $6.65.